Prognostic value of DcR3 in solid tumors: A meta-analysis

被引：9

作者：

Ge, Hua ^{[1
]}

Liang, Chaojie ^{[1
]}

Ren, Shulin ^{[1
]}

Yue, Chaosen ^{[1
]}

Wu, Jixiang ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Tongren Hosp, Dept Gen Surg, 2 Chongwenmennei St, Beijing 100730, Peoples R China

来源：

CLINICA CHIMICA ACTA | 2018年 / 481卷

关键词：

Decoy receptor 3; Solid tumors; Prognosis; Meta-analysis; SOLUBLE DECOY RECEPTOR-3; DOWN-REGULATION; FAS LIGAND; CARCINOMA; CELL; EXPRESSION; OVEREXPRESSION; SUPERFAMILY; BIOMARKERS; APOPTOSIS;

D O I：

10.1016/j.cca.2018.02.038

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Background: Decoy receptor 3 (DcR3) has been reported to be overexpressed in a wide range of solid tumors, suggesting that DcR3 plays a crucial role in the development and progression of cancer. The present meta analysis assesses the association between DcR3 expression and prognosis in patients with solid tumors. Methods: Eligible studies were identified by searching the PubMed, Web of Science, Cochrane Library, EMBASE, Chinese CNKI, and Wan Fang databases. The pooled hazard ratios (HRs) for overall survival (OS) and recurrence free survival (RFS) were calculated using fixed effects models and random effects models, respectively. Results: Data from the 16 included studies, with 2209 patients, were reviewed and analyzed. DcR3 over expression was significantly associated with worse OS in patients with solid tumors, but its expression might not be related to RFS in malignancies. Conclusions: Current evidence demonstrates that increased DcR3 expression correlates with a poor prognosis in cancer patients, which suggests that the expression status of DcR3 is a useful biomarker for the prediction of prognosis in patients with solid tumors.

引用

页码：126 / 131

页数：6

共 44 条

[1]

[Anonymous], J MOD ONCOL

[2] The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3 [J].